More M&A Deals Could Boost Biotech ETFs

By
Devon Layne
December 12, 2012
Share:

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)

 

Head over to ETFtrends.com to learn more about ETFs within the biotech sector.

ETF DAILY DATA

Van Eck's chip ETF 'SMH' doubled its assets on Tuesday, March 31, as total U.S.-listed ETF assets ended the day at almost $2.1 trillion.

'VDE' paced Vanguard's issuer-leading inflows on Tuesday, March 31, as total U.S.-listed ETF assets ended the day at nearly $2.1 trillion.

ETF.COM ANALYST BLOGS

By Dave Nadig

How Ric Edelman is reinventing the ‘new economy’ investing paradigm.

By Olivier Ludwig

What’s cooler than an ETF with a ticker like ‘HACK’? The way investors are using it.

By Olivier Ludwig

Yes, 2015 is shaping up to be the ‘year of currency hedging,’ but that’s not necessarily a good thing.

By Elisabeth Kashner

ETF.com steps in to referee a catfight that has erupted in the world of robo advisors.